Brought to you by 
Icos and Suntory form 50/50 joint venture, Suncos Corp.
16 Mar 2005
Executive Summary
Suntory and Icos formed a 50/50 joint venture, Suncos Corp., to develop and commercialize an Icos therapeutic agent, recombinant platelet-activating factor acetylhydrolase to treat acute respiratory distress syndrome, acute pancreatitis and asthma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Icos and Suntory form 50/50 joint venture, Suncos Corp.
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice